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Abstract
Prognosticators evaluating survival in breast cancer vary in significance in respect to lymph node
status. Studies have shown e.g. that HER2/neu immunohistochemistry or HER2/neu gene
amplification analysis do perform well as prognosticators in lymph node positive (LN +) patients
but are less valuable in lymph node negative (LN -) patients. We collected data from different
studies and tried to evaluate the relative significance of different prognosticators in LN+/LN-
patient groups. In LN+ patients HER2/neu and E-cadherin immunohistochemistry were the
statistically most significant prognosticators followed by proliferation associated features (mitotic
counts by SMI (standardised mitotic index) or MAI (mitotic activity index), or S-phase fraction). Bcl-
2 immunohistochemistry was also significant but p53 and cystatin A had no significance as
prognosticators. In LN- patients proliferation associated prognosticators (SMI, MAI, Ki-67 index,
PCNA immunohistochemistry, S-phase fraction) are especially valuable and also Cathepsin D,
cystatin A, and p53 are significant, but HER2/neu or bcl-2, or E-cadherin less significant or without
significance. We find that in studies evaluating single prognosticators one should distinguish
between prognosticators suitable for LN+ and LN- patients. This will allow the choice of best
prognosticators in evaluating the prospects of the patient. The distinction between LN+ and LN-
patients in this respect may also be of special value in therapeutic decisions.
Background
Breast cancer is the most common cancer among women
and the second leading cause of cancer deaths in women
today. For example, 212,920 new cases of invasive breast
cancer are expected to be diagnosed among women in the
United States in 2006 (1.4 new cases among 1000
women) [1]. In Finland, according to the Finnish Cancer
Registry, about 3800 females are diagnosed with breast
cancer every year (1.5 new cases among 1000 women)[2].
Improved methods of detection and treatment of breast
cancer have had a significant influence on disease out-
come [3]. The main challenge today is to find factors
which could predict the patients who have a tumor with
aggressive nature. There are a lot of data on clinical prog-
nostic factors such as axillary lymph node (LN) status,
tumor size, histological grade, and clinical stage. Breast
cancer treatment could be based on these factors [4].
However, additional factors have also been used such as
estrogen receptor (ER) positivity, progesterone receptor
(PR) positivity, and HER2/neu status. The latter are con-
sidered especially useful in identifying patients who ben-
efit from systemic adjuvant therapy. The International
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Consensus Panel of St. Gallen determined the standard
prognostic factors of breast cancer as follows: LN status,
ER and PR, tumor size, histological grade, and age [5].
These prognostic factors have been used to identify the
high-risk patients who may benefit from the adjuvant sys-
temic therapy. However, still there is an urgent need for
finding biological factors which could help in planning
the future therapy of breast cancer.
Here we review several biological prognostic factors and
associate their prognostic role with the lymph node status.
Such grouping could help clinicians to create tailored and
more individualized prognostic models which could help
in choosing the right treatment for individual patients.
Earlier research has shown that prognosticators vary
between LN+ and LN- patients. Table 1 shows the charac-
teristics of a few studies we will refer to in the following.
Differences in the size and other characteristics of the
studied populations make comparison between different
reports difficult. Most of the studied populations are Cau-
casian (white), but in two American studies, there is also
a fraction of black patients [37,68]. Because populations
may differ in prognostic characteristics, we have decided
to stress this point [1,65]. Most studies do not include
adjustment for age and there are studies which do not nec-
essarily clearly describe how cutpoints for each prognostic
marker were defined. [In writing this review, however, we
have expected that the authors have been able to select the
most significant cutpoint for each prognosticator studied
(see e.g. [123])].
Oncogenes and tumor suppressor genes
C-erbB-2 (HER2) or HER2/neu
HER2/neu proto-oncogene encodes a 185-KDa trans-
membrane glycosylated epidermal growth factor receptor
that contains an extracellular domain and has intracellu-
lar tyrosine kinase activity [6]. Amplification of the HER2/
neu gene and overexpression of its protein are known to
be characteristic of many breast cancers [7-9]. Several
Table 1: Survival associated tissue-section-based prognostic factors and lymph node status in breast cancer.
Prognosticator N Age range 
or median
Country Methods Stage/LN status 
of all patients
Stength of 
association 
(survival %)*
P value, type 
of analysis
Mean or median 
follow-up (months)
Reference
LN+ patients
AgNOR 164 N.A. Italy MA N-, N+ DFS (42,61) 0.0093 M 108 Derenzini90
Bcl-2 107 56 Belgium IHC N-, N+ DFS (21,62) <0.001 U 91 Hellemans55
CD44 74 62 Finland IHC N-, N+ DSS (45,56) 0.02 U 84 Joensuu158
E-cadherin 57 59 Finland IHC N-, N+ OS (36,88) 0.0001 U 66.5 Elzagheid150
EGFR 404 53.4 Japan IHC N-, N+ DFS (50,75) <0.0001 U 46 Tsutsui110
ER 705 54 UK IHC I-IV DFS, ReR 0.651 0.004 M 62 Rehim122
HER2/neu 106 59 Finland IHC N-, N+ OS (13,80) 0.001 U 67.2 Jalava16
IGF-1 98 57.1 Finland IHC N-, N+ OS (16,35) 0.0286 U 169.2 Toropainen115
Mitoses 131 59 Finland SMI N-, N+ RR 3.5 0.0005 U 69 Kronqvist71
Mitoses 368 25–81 MC MAI N+ OS (57,83) 0.00003 U 60 Simpson68
P21 328 N.A. USA IHC N-, N+ DFS, X2 74.61 0.054 M 195.6 Thor 37
PgR 106 58 Finland IHC N-, N+ N.A. 0.0186 70 Jalava 123
SPF 257 25–81 MC FCM N+ OS (70,82) 0.026 U 60 Simpson68
LN- patients
Ploidy 50 56 UK FCM N- DFS (32,71) <0.0001 U >120 Yuan132
Cathepsin D 262 60 Finland IHC N- DFS (47,68) <0.0001 U 98.4 Isola100
CD44 237 56 Holland IHC N-, N+ DFS (50,75) 0.005 U 84 Foekens156
EGFR 618 53.4 Japan IHC N-, N+ DFS, ReR 2.05 0.0241 M 46 Tsutsui110
HER2/neu 324 N.A. USA FISH N- DFS (57,75) 0.0077 U 50 Press17
HER2/neu 224 59 Finland IHC N-, N+ N.A. N.S. 67.2 Jalava16
Ki-67 89 60.5 Finland IHC N-, N+ OS (50,70) 0.0297 U 103.2 Pietilainen78
Mitoses 516 <55 MC MAI N- DFS (62,85) <0.00001U 118 Baak69
Mitoses 232 59 Finland SMI N-, N+ RR 4.2 0.0007 U 69 Kronqvist71
P27 75 <65 Canada IHC N-, N+ DSS, ReR 0.24 0.03 M 180 Foulkes47
P53 700 <50 USA IHC N- DFS (53,85) 0.0001U 54 Allred33
PCNA 205 60.5 Finland IHC N- DFS (56,80) 0.0003 U 141.6 Aaltomaa84
SPF 180 N.A. China N.A. N- N.A. <0.001 60 Zhang 96
Prognosticators for LN+ patients are presented first followed by those for LN- patients. The database applied was PubMed, the presented papers 
were published during years 1991–2005. The most significant p-values with defined survival characteristics for each marker are shown. P-values are 
not comparable with each other in absolute terms because also the size of the sample influences the p value. The value of prognosticators can only 
be compared reliably by comparing different prognosticators in the same patient material.
* The figures within the parantheses refer to the survival of 2 cutpoint-associated patient groups after median follow up. IHC, 
immunohistochemistry; N-, node negative; N+, node positive; MA, morphometric analysis; FCM, flow-cytometry; NA, not available; MC, 
multicenter study; SMI, standardized mitotic index; MAI, mitotic activity index; OS, overall survival; DFS, disease free survival; DSS, disease specific 
survival; RR, risk ratio; ReR, relative risk; X2, Chi square;, FISH, fluorescence in situ hybridization; N.S, not significant; M, multivariate; U, univariate.Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
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studies have correlated the overexpression of the HER2/
neu oncogene with poor prognosis in breast cancer
patients [10,11], and demonstrated that evaluating HER2/
neu protein by immunohistochemistry (IHC), fluores-
cence in situ hybridization (FISH), and chromogenic in
situ hybridization (CISH) are important in selecting opti-
mal therapy and predicting prognosis in breast cancer
patients [12-14]. Slamon et al. and Jalava et al. [15,16],
showed that intensive HER2/neu immunostaining was a
highly significant negative prognosticator in LN+ patients
(especially postmenopausal), but not a significant prog-
nosticator among LN- patients or patients younger than
52 years. The paper of Jalava et al. [16] suggested that the
size of the patient group which absolutely seemed to need
the targeted therapy against the amplified HER2/neu
receptor was at least 2% of all breast cancer patients. Press
et al. [17], however, suggested that HER2/neu is a signifi-
cant prognosticator in LN- patients. However, there is still
no perfect consensus on which method is most predictive
of positive patient response to trastuzumab, also known
as Herceptin, a monoclonal antibody that selectively tar-
gets HER2/neu. Tawfik et al. [18] discussed the results
from a study comparing HER2/neu expression and gene
amplification in the same patients by IHC using auto-
mated cellular imaging system (ACIS) and by FISH. They
concluded that HER2/neu assessment by IHC-ACIS corre-
lates highly with results obtained by FISH. The concord-
ance rate between two methods was 94%. Isola et al. [19]
showed that CISH could provide an accurate and practical
alternative to FISH for clinical diagnosis of HER2/neu
oncogene amplification in archival formalin-fixed breast
cancer samples. Seidman and associates [20] reported that
the overall response rate (for combination paclitaxel and
trastuzumab) in patients with HER2/neu overexpression
ranged from 67% to 81%, compared with 41% to 46% in
patients with tumors having normal Her-2 expression. In
agreement with them Joensuu et al., Piccart-Gebhart et al.,
and Romond et al. [21-23] demonstrated positive
response among patients showing HER2/neu amplifica-
tion or intensive membrane staining by immunohisto-
chemistry. The effect was clear in disease-free- survival and
overall survival in freedom from distant metastases.
P53
Early observations after the identification of the p53 pro-
tein suggested that p53 functioned as an oncogene. In fact
it does, but only in the mutated form. In the late 1980s,
however, several discoveries proved that the normal func-
tion of p53 was anti-oncogenic. One of the several func-
tions of the normal p53 gene is suppression of cell
proliferation. When DNA is damaged p53 inhibits the
progression of cell cycle from G1 to the S-phase or during
S-phase [24-26]. The mutation of the p53 gene has been
detected in almost 50% of human cancers including
breast cancer [27-29]. Several studies demonstrated that
mutations of p53 or increased nuclear expression of p53
protein is a prognostic factors in breast cancer, and associ-
ated with worse prognosis [30-32]. Allred and associates
[33] showed that p53 predicted disease free survival in
patients with LN- breast cancer. Expression of mutant p53
protein was associated with early disease recurrence and
early death in LN- breast cancer. The results of Kuopio et
al. [34] clearly support the latter finding. In their series
immunohistochemical positivity of p53 was a significant
prognosticator among all and LN- patients, but did not
show significance among LN+ patients.
P21
p21 (WAF) is an inhibitor of cyclin-dependent kinase. It
plays a central role both in the regulation of the cell cycle
and in the DNA replication [35]. p21 (WAF) is regarded as
a putative tumor suppressor and its role in breast cancer is
still unclear. p21 (WAF) might have a functional role in
the inhibition of PCNA mediated DNA replication [35].
So far there is not much evidence that p21 (WAF) could
be used as a prognostic factor in breast cancer [36]. Thor
and co-workers demonstrated marginal independent
prognostic significance of the p21 (WAF) in the LN+ set of
patients, whereas p21 status was not significantly associ-
ated with survival among LN- patients [37]. Ras p21 is a
guanine nucleotide-binding protein that is involved in the
signal transduction pathway that control cell proliferation
[38,39]. The ras gene is rarely mutated in breast tumors,
but is overexpressed in 50–60% of breast tumors [40].
Rundle et al. suggested that the presence of ras p21 in
blood is associated with a five fold increased risk of breast
cancer [41]. Czerniak et al. found that p21 expression was
significantly higher in cancer cells than in epithelial cells
of control specimens. As a group, tumors with axillary
lymph node metastases expressed higher levels of ras p21
than nonmetastasizing tumors [42].
P27
P27 is a cyclin dependent kinase inhibitor, which may act
as a potential suppressor gene. Reduction of p27 expres-
sion is related to uncontrolled cell proliferation and tum-
origenesis. P27 acts in G1 to inhibit cyclin-cdks [43,44].
Several studies have suggested that low expression of p27
is an independent factor weakly associated with poor
prognosis [45,46]. Foulkes and his co-workers (2004)
[47] demonstrated that the level of p27 was one of inde-
pendent predictors in LN- patients but not in LN+
patients.
C-myc
Amplification of the c-myc gene is found in 20% of pri-
mary breast cancers, and this is more frequent in larger
tumors, and in lymph node positive patients [48]. Over-
expression and other alterations of c-myc gene may be
related to breast cancer progression. It can be expectedDiagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 4 of 12
(page number not for citation purposes)
that c-myc has a potential as a marker of poor prognosis
[49,50]. We did not find c-myc associated prognostic
information which was related to the lymph node status.
Bcl-2
Bcl-2 gene encodes for a mitochondrial protein thought to
prevent apoptosis in normal cells. Dysregulation of this
gene can contribute to tumor progression and increased
drug resistance [51,52]. Bcl-2 expression was associated
with favourable prognosis in breast cancer and was both
estrogen receptor(ER) and progesterone receptor (PR)
associated [53,54]. Several studies have demonstrated the
independent favourable prognostic impact of Bcl-2 on
breast cancer particularly among LN+ patients [55,56]. It
is obvious that the prognostic value of Bcl-2 staining
among all patients is solely based on prognostic applica-
bility among LN+ patients because the association among
LN- patients is clearly non significant [57].
Cell proliferation
Mitotic count
Evaluation of proliferation activity of the neoplastic cells
gives important prognostic information, especially in
breast cancer [58,59]. There are many available ways to
measure cell proliferation, including the determination of
the mitotic rate by counting the mitotic figures [60,61].
Mitotic counts are performed by counting the number of
mitoses from ten high power fields (Baak et al. ; mitotic
activity index; MAI), or by expressing the count by square
millimeter, which produces the standardised mitotic
index (SMI) [62], or volume fraction corrected mitotic
index (M/Vv index) [63,64]. Many studies demonstrated
that the MAI is an independent prognostic factor for recur-
rence free survival [65,66]. SMI is a bit more efficient than
MAI as a prognosticator [67]. Simpson et al. [68] showed
that determination of mitotic activity is able to identify a
group with improved disease free and overall survival
among patients with LN+ breast cancer. The mitotic activ-
ity is also an independent prognostic marker in LN- breast
cancer patients younger than 55 years [69]. Baak and his
co-worker also found that the LN- patients with MAI > 10
are at risk for distant metastases, similar to LN+ [70]. SMI
was a highly significant prognosticator among all patients
but especially among LN- patients [71]. Among LN+
patients this marker was less significant. It is surprising in
light of numerous ways to measure proliferative activity
how consistently the mitotic count emerges as the most
powerful prognosticator. All ways of estimation are prog-
nosticators but the mitotic count is the strongest one in
the majority of comparing studies.
Ki-67
Ki-67 antigen is one of several cell-cycle regulating pro-
teins which can be determined by immunohistochemistry
[72,73]. It is expressed in proliferating G1-, S- and G2/M-
phase nuclei [74,75]. Because most of the Ki-67 positive
cells are in the cell cycle, Ki-67 labelling index (fraction of
Ki-67 positive nuclei of all nuclei) reflects the fraction of
proliferating cells. Many studies demonstrated the associ-
ation between a high Ki-67 labelling index, histological
grade and large tumor size in breast carcinoma [76,77].
Ki-67 labelling index (determined e.g. by the MIB1 anti-
body; an IgG monoclonal antibody used for detection Ki-
67) has prognostic value in breast cancer, particularly in
LN- patients [78,79]. However, the prognostic signifi-
cance is less than that of mitotic count (as determined
with either MAI or SMI). However, there is some evidence
that 3-dimensional analysis of Ki-67-positive nuclei may
improve the prognostic power of Ki-67 immunohisto-
chemistry [80].
PCNA
Proliferating cell nuclear antigen (PCNA) is a DNA-
polymerase-related protein which is expressed in all pro-
liferating cells. The expression is increased during G1
phase, S-phase and declines during G2/M [81]. Many
reports observed that PCNA shows prognostic value in
breast cancer [82,83]. Aaltomaa and his coworkers stated
that the prognostic significance of PCNA can be demon-
strated especially among LN- patients [84]. They did not
include LN+ patients in their study.
AgNOR
Argyrophilic nucleolar organizer regions (AgNOR) corre-
late with the proliferative activity of neoplasms. Increased
AgNOR counts may reflect increased proliferative activity
of cells [85,86]. AgNOR counts have been studied in
breast carcinoma, but the results have been conflicting.
Some studies have demonstrated that quantitative analy-
sis of AgNORs yields a prognostic factor in breast cancer
[87,88]. The combination of MIB-1- immunopositivity
and AgNOR measurements in MIB-1 positive nuclei
improves prognostication [89]. Derenzini et al. reported
that AgNOR has a prognostic value specially among LN+
patients [90]. Others were not able to find prognostic sig-
nificance in AgNOR counts for breast cancer [91,92].
S-phase fraction (SPF)
The histogram describing the nuclear DNA content deter-
mined by flow cytometry can be used as an estimate of the
proliferation rate. The measurement estimates the fraction
of cells in the S phase (S phase fraction), which reflects
proliferative activity. The S-phase fraction (SPF) is a rough
estimate of neoplastic growth rate. Several reports
observed the prognostic value of SPF in breast cancer
[93,94]. Low SPF is associated with an excellent prognosis
in LN- breast patients [95-97]. Based on the grading effi-
ciency analysis [98] SPF estimation from isolated nuclei
may reach efficiencies comparable to that of mitotic
counts.Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
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Cathepsin D (CD)
Cathepsin D is a 52-kd protein, precursor to a lysosomal
acidic protease. This proteolytic enzyme can degrade base-
ment membranes. It has mitogenic activity on MCF-7 cells
that are estrogen depleted and contributes to prolifera-
tion, invasion, and progression in breast [99]. Several
studies have demonstrated that Cathepsin D is an impor-
tant prognostic factor in breast cancer, especially in LN-
patients [100,101]. In the report by Rochefort [102] over-
expression of cathepsin D was associated with increased
risk of metastasis, but there are also studies that failed to
find prognostic significance of cathepsin D in breast can-
cer [103,104].
Growth factors
Epidermal growth factor receptor (EGFR)
EGFR is a member of the tyrosine kinase growth factor
receptor family. EGFR and its ligand, transforming growth
factor-alpha (TGF-alpha) play an important role in several
human cancers [105,106], through the autocrine growth-
regulation system in breast cancer, EGFR has been
reported to be associated with a poor clinical outcome
[107,108]. Rampaul and his co-workers found that the
EGFR was significant only in lymph node positive breast
cancer patients [109], with high expression reflecting
worse outcome. Tsutsui et al. reported that a combination
of EGFR and ER was an independent significant factor for
both disease free survival (DFR) and overall survival (OS)
both in patients with LN- and LN+ breast cancer. Patients
with EGFR (+) and ER (-) had worse DFS and OS [110].
Insulin-like growth factor (IGF)
IGF1 and IGF2 are circulating peptide hormones and
locally acting growth factors with both paracrine and
autocrine functions. Both IGF1 and IGF2 are involved in
the regulation of cell proliferation and apoptosis [111].
Many observers suggested that IGFs are involved in the
progression of breast cancer [112,113]. The presence of
IGF-1 immunoreactivity in breast cancer epithelial cells
indicates a lower degree of malignancy than the lack of
IGF1 [114]. Toropainen et al. reported that, in a univariate
analysis, IGF-1 was significantly related to a high survival
probability particularly in LN+ breast cancer patients
[115].
Estrogen (ER) and progesterone (PR) receptors
Since breast cancer is one of the hormone dependent
tumors much attention has been paid to the relationship
between ER and PR and breast cancer. The study by Blanco
et al. (1984) [116] showed that ER+ PR+ patients had bet-
ter prognosis than ER- PR- patients. In late 1970's and
early 1980's the measurement of ER as well as PR became
standard practice in the prediction of the outcome of
breast cancer patients [117-119]. The immunohistochem-
ical analysis of ER and PR has replaced the traditional and
also clinically validated dextran charcoal radioactive lig-
and binding assay [120]. The prognostic value of ER and
PR seems to be greater among axillary LN+ than among
LN- patients [121,122]. The study of Jalava et al. [123]
showed that immunohistochemical ER score is associated
with prognosis. However, cutpoints for defining the
groups with good or worse prognosis may differ between
LN- and LN+ patients.
DNA content
Cytometric quantitation of nuclear DNA content can
assist in the diagnosis and grading of malignant tumors
[124]. A great number of studies using flow cytometry and
static image cytometry suggested that nuclear DNA con-
tent has a significant value in prognosis of breast cancer
[125-127]. Tumors with DNA peaks within diploid limits
have a more favorable prognosis than those with aneu-
ploid peaks [128,129]. Nuclear DNA content strongly cor-
related to histopathologic grade of ductal carcinoma.
Histologic grade 3 tumors were more likely to be aneu-
ploid than others [130,131]. Many observers stated that
aneuploid tumors were associated with a poorer progno-
sis than diploid tumors in LN- breast cancer patients
[132,129]. However, an adverse correlation was stated by
Chassevent et al. They confirmed that ploidy status had no
prognostic impact in the overall population or in sub-
groups defined by lymph node status [133]. Moureau-
Zabotto et al. suggested that combination of DNA ploidy
and SPF predict patients out-come particular in LN- breast
cancer patients [134]. DNA ploidy results can be com-
bined with other features in efficient evaluation of prog-
nosis [135].
Nuclear morphometry
Baak and his coworkers (1985) were among the pioneers
in introducing morphometry for prognostication of breast
cancer [62]. They found that morphologic features are
associated with high risk in pre-invasive breast cancer. The
independent prognostic value of nuclear variables was
established in several studies on infiltrating breast cancer
[136]. Nuclear area and diameter were shown to be useful
prognostic factors. However, nuclear diameter has failed
to separate the primary tumor from its metastasis [137].
Patients with high nuclear area values and high SD of
nuclear area values tend to have poor prognosis [138].
High mean nuclear area is related to poor histological
grade [139]. Evaluation of nuclear area can be used for
morphometric grading of breast cancer [140]. The latter
study also showed that the nuclear area was a significant
prognosticator among LN+ and all patients, but com-
pletely lacked significance among LN- patients.Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
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Adhesion molecules
E-cadherin
Cell adhesion molecules play an important role in the
maintenance of tissue architecture [141]. E-cadherin is a
member of a family of transmembrane glycoproteins that
mediate homotypic calcium dependent cell-to-cell adhe-
sion in epithelial tissues [142]. Loss of normal function of
E-cadherin is known to promote cancer invasion in sev-
eral human cancers [143]. Several studies have demon-
strated that reduced E-cadherin expression is an indicator
of increased invasiveness and dedifferentiation in breast
cancer [144,145]. A recent study found that the expression
of E-cadherin correlates with histological type and grade
[146]. The expression of E-cadherin in infiltrative lobular
carcinoma was completely negative or weakly positive
whereas infiltrating ductal carcinoma showed greater
immunoreactivity in grade 1 breast carcinoma than in
grade 2 and grade 3 carcinomas [147]. There was an
inverse relationship between E-cadherin expression and
axillary lymph node involvement. Reduction in E-cad-
herin expression was associated with the involvement of
the axillary lymph nodes [148]. Gamallo and his associ-
ates [149], and Lipponen and his co-worders [142] did
not agree with this finding. Siitonen et al. [144] showed
that reduced E-cadherin expression was independently
associated with shorter disease free survival. Other
authors stated that the prognostic value of E-cadherin was
stronger among patients with LN+ breast cancer [150,151]
than among all patients. However, there was no signifi-
cant association with prognosis among LN- patients
[150]. The latter findings can explain the variable findings
by different research groups on the prognostic significance
of E-cadherin among all breast cancer patients.
Catenins
Intracellular proteins (α-β-γ-catenins), are associated with
E-cadherin's cytoplasmic tail and link actin to the micro-
filament network of the cellular cytoskeleton. This bind-
ing is essential for the adhesive function of E-cadherin
[152]. Alterations in expression of catenins may lead to
the disassembly of cadherin junctions and to the genera-
tion of more invasive cells [153]. Many studies have sug-
gested that loss of E-cadherin and catenin expression may
be associated with poor prognosis of breast cancer
[154,155]. We did not find any reports of catenins associ-
ated with prognostic data which is related to the lymph
node status.
CD 44
CD44 is a family of cell surface transmembrane glycopro-
teins which is expressed in a wide variety of tissues and
cell types [156,157]. In human breast cancer, the prognos-
tic value of the various isoforms has not been recognized
as independent predictors of breast cancer outcome
[158,159]. Foekens and co-workers [156] stated that the
expression of exon v6 of CD44 may be a marker for iden-
tifying patients with relatively favourable prognosis
among LN- patients.
Extracellular matrix
Tenascin
Tenascin is a glycoprotein of the extracellular matrix and
appears in the stroma of benign and malignant tumors
[160]. Many studies have stated that loss of tenascin
expression in breast cancer cells appears to indicate poor
prognosis [161,162]. So far we do not have knowledge of
differences in the prognostic value between LN + and LN
- patients.
Matrix metalloproteinases (MMPs)
MMPs are a family of proteinases that play an important
role in malignant tumor growth, invasion, metastasis and
angiogenesis [163,164]. High expression levels of MMPs
in tumor tissue are usually associated with poor survival
[165]. In breast cancer, Talvensaari-Mattila and his cow-
orker [166] demonstrated that overexpression of MMP-2
is associated with poor prognosis. Prognostic data on LN
+ and LN - patients are not available.
Cystatin A
Cystatin A is a natural cysteine proteinase inhibitor and is
found in a wide variety of normal cells. The physiologic
role of Cystatin A is not fully known, however. Cystatin A
is present in large amounts in follicular dendritic cells in
lymphoid tissues [167]. In malignant tissues, cystatin A
has been found in many tumors including breast cancer
[168]. In breast cancer patients, Kuopio et al. (1998) dem-
onstrated that the expression of cystatin A was associated
with poor outcome; the study also showed that cystatin A
was a prognostic marker for LN- patients. In LN+ patients,
cystatin A was without significance [34].
Grading
Various histological grading systems of breast carcinoma
have been described [169-171]. The majority of tumor
grading systems combine nuclear grade, tubular forma-
tion and mitotic rate. In Europe, Elston and Ellis (1991)
stressed the importance of careful grading [172] and cor-
responding approach has become increasingly popular in
the US [173,68]. It was suggested that the histological
grade functions best as a prognosticator in LN- patients for
making decision when tumor sizes fall between tumor
size categories [174]. The applied histological features can
be measured morphometrically [71,140,175], making the
grading system robust and reproducible. The multivariate
grading methods [62,176-178] are comparable or better
than grading methods alone and can be expected to be
more reproducible. However, the performance in group-
ing of the patients in low and high grade categories is not
necessarily identical because these grading methods wereDiagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
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originally based on different patient materials [179]. It is
important to notice that most multivariate methods
include lymph node status as a contributing feature and
for that reason multivariate methods or indices are appli-
cable to both LN+ and LN- patients. This also applies to
the Nottingham prognostic index which combines tumor
size, lymph node status, and histological grade [172]. So
far, however, there are few studies comparing traditional
and multivariate grading in clinical practice or in different
patient groups in terms of power to finding patients with
bad prognosis. But we know that different individual
prognostic factors and grading systems often give parallel
results. For example: when DNA ploidy status is diploid,
histological grade is generally low, and when DNA ploidy
is aneuploid, histological grade is higher [180]. If histo-
logical grade is used as the basic classifier of patients into
treatment groups, DNA ploidy can be used as a method to
confirm the classification especially in situations of uncer-
tainty. In the same way, other biological prognosticators
can and probably should be applied in clinical practice.
Conclusion
Mitotic activity indices (SMI or MAI) are the most power-
ful general prognostic markers and highly associated with
survival in LN+ patients and in LN- patients younger than
55 years old.
E-cadherin was the second most important prognostic
marker in patients with LN +, followed by HER2/neu. In
LN- patients, cathepsin D was the second most important
prognostic marker followed by HER2/neu, SPF, and aneu-
ploidy.
Table 1 lists histological prognostic markers in LN- and
LN+ breast cancers. Because the presented survival associ-
ated significances are based on different studies, they are
not directly comparable. However, reliable comparison in
term of prognostic value can be done after univariate anal-
ysis in the same group of patients. Multivariate analysis is
less suitable for comparison of variables because the goal
of the multivariate analysis is the removal of the prognos-
tic overlaps. The strength of association can be evaluated
either by risk ratio, relative risk, or comparison of the sur-
vival curves defined by 2 cutpoint associated patient
groups in respect to disease free survival (DFS), overall
survival (OS), or disease specific survival (DSS). The dif-
ference in the importance of prognosticators is presented
in Table 2. Generally, comparison is made difficult by the
lack of standardized study protocols. Table 2 shows, how-
ever, that prognosticators vary in terms of stage: the sur-
vival of LN- and LN+ patients can best be predicted with
prognosticators specific to the LN status.
We conclude that studies on prognostic evaluation of new
potential markers in breast cancer should not be under-
taken without studying the prognosis among all patients,
and separately among LN + and LN - patients. Corre-
spondingly the use of prognosticators for clinical decision
making should be based on the gathered knowledge of
differences between LN + and LN - patients.
Acknowledgements
This work was supported by Cancer Society of South-West Finland, Turku, 
and by special government Funding (EVO) allocated to Turku University 
Central Hospital.
References
1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun
M: Trends in breast cancer by race and ethnicity: update
2006.  CA A Cancer J Clin 2006, 56:168-183.
2. Finnish Cancer Registry: Cancer in Finland. 2002 and 2003.
Cancer statistics of the National Research and Development
Centre for Welfare and Health. Cancer Society of Finland.
Publication No. 66, Helsinki 2005. ISSN 0585-9603
3. Levi F, Lucchini F, Negri E, La Vecchia C: Worldwide patterns of
cancer mortality, 1990–1994.  Eur J Cancer Prev 1999,
8(5):381-400.
4. Fisher ER, Anderson S, Redmond C, Fisher B: Pathologic findings
from the National Surgical adjuvant breast project protocol
B-06. 10-year pathologic and clinical prognostic discrimi-
nants.  Cancer 1993, 71(8):2507-14.
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B,
Senn HJ: Meeting highlights: updated international expert
consensus on the primary therapy of early breast cancer.  J
Clin Oncol 2003, 21(17):3357-65.
Table 2: Comparison of different prognosticators in single 
studies on breast cancer.
LN + Prognosticator P value
Kuopio et al. 1998 [34]
1. Bcl-2 0.017
2. p53 0.121
3. Cystatin A 0.386
Jalava et al. 2002 [16]
1. ErbB2 0.0002
2. SMI 0.0014
3. Bcl-2 0.048
Elzagheid et al. 2002 [150]
1. E-cadherin 0.0006
2. SMI 0.0133
LN -
Kuopio et al. 1998 [34]
1. Cystatin A 0.010
2. p53 0.021
3. Bcl-2 0.874
Jalava et al. 2002 [16]
1. SMI 0.0001
2. ErbB2 N.S.
3. Bcl-2 N.S.
Elzagheid et al. 2002 [150]
1. SMI 0.0299
2. E-cadherin 0.5581
P values refer to the results of univariate analysis. Comparison of 
univariate analyses in a study allows one to conclude on the relative 
strengths of different prognosticators.Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 8 of 12
(page number not for citation purposes)
6. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Car-
ney W, Allard JW, Lipton : Relationship of serum HER-2/neu and
serum CA 15-3 in patients with metastatic breast cancer.
Clin Chem 2002:1314-20.
7. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-
erbB-related gene in a human mammary carcinoma.  Science
1985, 229(4717):974-6.
8. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris
R, Shiloh Y, Givol D, Schlessinger J: Sporadic amplification of the
HER2/neu protooncogene in adenocarcinomas of various tis-
sues.  Cancer Res 1988, 48(6):1517-20.
9. Devilee P, Schuuring E, van de Vijver MJ, Cornelisse CJ: Recent
developments in the mol ecular genetic understanding of
breast cancer.  Crit Rev Oncog 1994, 5(2–3):247-70.
10. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a
prognostic and predictive marker in breast cancer: a para-
digm for the development of other macromolecular mark-
ers.  Gene 1995, 159(1):19-27.
11. Naidu R, Yadav M, Nair S, Kutty MK: Expression of c-erbB3 pro-
tein in primary breast carcinomas.  Br J Cancer 1998,
78(10):1385-90.
12. Yeh IT: Measuring HER-2 in breast cancer. Immunohisto-
chemistry, FISH, or ELISA?  Am J Clin Pathol 2002,
117(Suppl):S26-35. Review
13. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cyto-
plasmic p21WAF1/CIP1 expression is correlated with HER-
2/neu in breast cancer and is an independent predictor of
prognosis.  Breast Cancer Res 2003, 5(6):R242-9.
14. Gu M, Ghafari S, Zhao M: Fluorescence in situ hybridization for
HER-2/neu amplification of breast carcinoma in archival fine
needle aspiration biopsy specimens.  Acta Cytol 2005,
49(5):471-6.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL:
Human breast cancer: correlation of relapse and survival
with amplification of the HER-2/neu oncogene.  Science 1987,
235(4785):177-82.
16. Jalava PJ, Kuopio T, Kortelainen S, Kronqvist P, Collan YU: Quanti-
tation of erbB2 positivity for evaluation of high-risk patients.
Ann Med 2002, 34(7–8):544-53.
17. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung
G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross
JS, Wolman SR, Flom KJ: HER-2/neu gene amplification charac-
terized by fluorescence in situ hybridization: poor prognosis
in node-negative breast carcinomas.  J Clin Oncol 1997,
15(8):2894-904.
18. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F,
Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ: Compar-
ison of immunohistochemistry by automated cellular imag-
ing system (ACIS) versus fluorescence in-situ hybridization
in the evaluation of HER-2/neu expression in primary breast
carcinoma.  Histopathology 2006, 48(3):258-67.
19. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM:
Interlaboratory comparison of HER-2 oncogene amplifica-
tion as detected by chromogenic and fluorescence in situ
hybridization.  Clin Cancer Res 2004, 10(14):4793-8.
20. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Pana-
geas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M,
Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristo-
fanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly
trastuzumab and paclitaxel therapy for metastatic breast
cancer with analysis of efficacy by HER2 immunophenotype
and gene amplification.  J Clin Oncol 2001, 19(10):2587-95.
21. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V,
Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeen-
niemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson
K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen
T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators: Adju-
vant docetaxel or vinorelbine with or without trastuzumab
for breast cancer.  N Engl J Med 2006, 354(8):809-20.
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch
M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D,
Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M,
Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter
TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden
E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study
Team: Trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer.  N Engl J Med 2005, 353(16):1659-72.
23. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein
PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemo-
therapy for operable HER2-positive breast cancer.  N Engl J
Med 2005, 353(16):1673-84.
24. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor
gene.  Nature 1991, 351(6326):453-6.
25. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW:
Participation of p53 protein in the cellular response to DNA
damage.  Cancer Res 1991, 51(23 Pt 1):6304-11.
26. Barnes DM, Camplejohn RS: P53, apoptosis, and breast cancer.
J Mammary Gland Biol Neoplasia 1996, 1(2):163-75.
27. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations
in human cancers.  Science 1991, 253(5015):49-53.
28. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC:
p53 is mutated in a subset of advanced-stage prostate can-
cers.  Cancer Res 1993, 53(14):3369-73.
29. Temmim L, Baker H, Sinowatz F: Immunohistochemical detec-
tion of p53 protein expression in breast cancer in young
Kuwaiti women.  Anticancer Res 2001, 21(1B):743-8.
30. Bergh J: Clinical studies of p53 in treatment and benefit of
breast cancer patients.  Endocr Relat Cancer 1999, 6(1):51-9.
31. Kalogeraki A, Panayiotides J, Tamiolakis D, Tzardi M, Chaniotis V,
Chalkiadakis G, Melissas J, Stiftsis D, Kanavaros P, Delides GS: P53
expression in patients with malignant and benign breast dis-
eases.  Anticancer Res 2000, 20(3A):1801-5.
32. Metcalfe S, Wheeler TK, Picken S, Negus S, Jo Milner A: P53 autoan-
tibodies in 1006 patients followed up for breast cancer.  Breast
Cancer Res 2000, 2(6):438-43.
33. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness
GC, Osborne CK, McGuire WL: Association of p53 protein
expression with tumor cell proliferation rate and clinical out-
come in node-negative breast cancer.  J Natl Cancer Inst 1993,
85(3):200-6.
34. Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T,
Weber E, Collan Y: Cysteine proteinase inhibitor cystatin A in
breast cancer.  Cancer Res 1998, 58(3):432-6.
35. Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf T:
p21(waf) correlates with DNA replication but not with prog-
nosis in invasive breast cancer.  J Clin Pathol 2001, 54(11):866-70.
36. Elledge RM, Allred DC: Prognostic and predictive value of p53
and p21 in breast cancer.  Breast Cancer Res Treat 1998, 52(1–
3):79-98.
37. Thor AD, Liu S, Moore DH 2nd, Shi Q, Edgerton SM: p(21WAF1/
CIP1) expression in breast cancers: associations with p53
and outcome.  Breast Cancer Res Treat 2000, 61(1):33-43.
38. Wiesmuller L, Wittinghofer F: Signal transduction pathways
involving Ras.  Cell Signal 1994, 6(3):247-67.
39. Medema RH, Bos JL: The role of p21ras in receptor tyrosine
kinase signaling.  Crit Rev Oncog 1993, 4(6):615-61.
40. Gulbis B, Galand P: Immunodetection of the p21-ras products
in human normal and preneoplastic tissues and solid tumors.
Hum Pathol 1993, 24(12):1271-85.
41. Rundle A, Tang D, Brandt-Rauf P, Zhou J, Kelly A, Schnabel F, Perera
FP: Association between the ras p21 oncoprotein in blood
samples and breast cancer.  Cancer Lett 2002, 185(1):71-8.
42. Czerniak B, Chen R, Tuziak T, Markiewski M, Kram A, Gorczyca W,
Deitch D, Herz F, Koss LG: Expression of ras oncogene p21 pro-
tein in relation to regional spread of human breast carcino-
mas.  Cancer 1989, 63(10):2008-13.
43. Barbareschi M: p27 Expression, a cyclin dependent kinase
inhibitor in breast carcinoma.  Adv Clin Path 1999, 3(4):119-27.
44. Chiarle R, Pagano M, Inghirami G: The cyclin dependent kinase
inhibitor p27 and its prognostic role in breast cancer.  Breast
Cancer Res 2001, 3(2):91-4.
45. Tsuchiya A, Zhang GJ, Kanno M: Prognostic impact of cyclin-
dependent kinase inhibitor p27kip1 in node-positive breast
cancer.  J Surg Oncol 1999, 70(4):230-4.
46. Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA,
Slingerland J, Foulkes WD: Germline BRCA1/2 mutations and
p27(Kip1) protein levels independently predict outcome
after breast cancer.  J Clin Oncol 2000, 18(24):4045-52.Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 9 of 12
(page number not for citation purposes)
47. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO,
Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter
P, Akslen LA: The prognostic implication of the basal-like (cyc-
lin E high/p27 low/p53+/glomeruloid-microvascular-prolifer-
ation+) phenotype of BRCA1-related breast cancer.  Cancer
Res 2004, 64(3):830-5.
48. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H,
Foekens JA: c-myc amplification is a better prognostic factor
than HER2/neu amplification in primary breast cancer.  Can-
cer Res 1992, 52(5):1107-13.
49. Naidu R, Wahab NA, Yadav M, Kutty MK: Protein expression and
molecular analysis of c-myc gene in primary breast carcino-
mas using immunohistochemistry and differential polymer-
ase chain reaction.  Int J Mol Med 2002, 9(2):189-96.
50. Aulmann S, Bentz M, Sinn HP: C-myc oncogene amplification in
ductal carcinoma in situ of the breast.  Breast Cancer Res Treat
2002, 74(1):25-31.
51. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti
M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: a prog-
nostic indicator strongly related to p53 protein in lymph
node-negative breast cancer patients.  J Natl Cancer Inst 1994,
86(7):499-504.
52. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB,
Recant WM: Overexpression of BCL-x protein in primary
breast cancer is associated with high tumor grade and nodal
metastases.  Cancer J Sci Am 1997, 3(4):230-7.
53. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D,
Anderson BO: Bcl-2 slows in vitro breast cancer growth
despite its antiapoptotic effect.  J Surg Res 1998, 76(1):22-6.
54. Park SH, Kim H, Song BJ: Down regulation of bcl2 expression in
invasive ductal carcinomas is both estrogen-and progester-
one-receptor dependent and associated with poor prognos-
tic factors.  Pathol Oncol Res 2002, 8(1):26-30.
55. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P,
Van Marck E: Prognostic value of bcl-2 expression in invasive
breast cancer.  Br J Cancer 1995, 72(2):354-60.
56. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar
PR, Ghosh N, Trivedi TI: Prognostic significance of immunohis-
tochemically localized biomarkers in stage II and stage III
breast cancer: a multivariate analysis.  Ann Surg Oncol 2000,
7(4):305-11.
57. Jalava PJ, Collan YU, Kuopio T, Juntti-Patinen L, Kronqvist P: Bcl-2
immunostaining: a way to finding unresponsive postmeno-
pausal N+ breast cancer patients.  Anticancer Res 2000,
20(2B):1213-9.
58. Laroye GJ, Minkin S: The impact of mitotic index on predicting
outcome in breast carcinoma: a comparison of different
counting methods in patients with different lymph node sta-
tus.  Mod Pathol 1991, 4(4):456-60.
59. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E,
Syrjanen K: Mitotic indexes as prognostic predictors in female
breast cancer.  J Cancer Res Clin Oncol 1992, 118:75-81.
60. Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic
index (M/V-INDEX). The standard of mitotic activity in neo-
plasms.  Pathol Res Pract 1989, 185:551-4.
61. Kujari HP, Collan YU, Atkin NB: Use of the mitotic counts for
the prognosis and grading of breast cancer. Method evalua-
tion study.  Pathol Res Pract 1994, 190(6):593-9.
62. Baak JP, Van Dop H, Kurver PH, Hermans J: The value of mor-
phometry to classic prognosticators in breast cancer.  Cancer
1985, 56(2):374-82.
63. Lipponen P, Papinaho S, Eskelinen M, Klemi PJ, Aaltomaa S, Kosma
VM, Marin S, Syrjanen K: DNA ploidy, S-phase fraction and
mitotic indices as prognostic predictors of female breast
cancer.  Anticancer Res 1992, 12:1533-8.
64. Collan YU, Kuopio T, Baak JP, Becker R, Bogomoletz WV, Deverell
M, van Diest P, van Galen C, Gilchrist K, Javed A, Kosma VM, Kujari
H, Luzi P, Mariuzzi GM, Matze E, Montironi R, Scarpelli M, Sierra D,
Sisti S, Toikkanen S, Tosi P, Whimster WF, Wisse E: Standardized
mitotic counts in breast cancer. Evaluation of the method.
Pathol Res Pract 1996, 192(9):931-41.
65. Ikpatt OF, Kuopio T, Collan Y: Proliferation in African breast
cancer: biology and prognostication in Nigerian breast can-
cer material.  Mod Pathol 2002, 15(8):783-9.
66. Groenendijk RP, Bult P, Noppen CM, Boetes C, Ruers TJ, Wobbes T:
Mitotic activity index in interval breast cancers.  Eur J Surg
Oncol 2003, 29(1):29-31.
67. Lipponen PK, Collan Y, Eskelinen MJ: Volume corrected mitotic
index (M/V index), mitotic activity index (MAI), and histolog-
ical grading in breast cancer.  Int Surg 1991, 76:245-9.
68. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist
KW, Pandya KJ, Page DL, Robert NJ: Prognostic value of histo-
logic grade and proliferative activity in axillary node-positive
breast cancer: results from the Eastern Cooperative Oncol-
ogy Group Companion Study, EST 4189.  J Clin Oncol 2000,
18(10):2059-69.
69. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Ver-
morken JB, Janssen EA: Prospective multicenter validation of
the independent prognostic value of the mitotic activity
index in lymph node-negative breast cancer patients
younger than 55 years.  J Clin Oncol 2005, 23(25):5993-6001.
70. Baak JP, Colpaert CG, van Diest PJ, Janssen E, van Diermen B, Alber-
naz E, Vermeulen PB, Van Marck EA: Multivariate prognostic
evaluation of the mitotic activity index and fibrotic focus in
node-negative invasive breast cancers.  Eur J Cancer 2005,
41(14):2093-101.
71. Kronqvist P, Kuopio T, Collan Y: Morphometric grading in
breast cancer: thresholds for mitotic counts.  Hum Pathol
1998:1462-8.
72. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse
monoclonal antibody reactive with a human nuclear antigen
associated with cell proliferation.  Int J Cancer 1983, 31(1):13-20.
73. Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM: Cell prolif-
eration measured by MIB1 and timing of surgery for breast
cancer.  Br J Cancer 1998, 77(9):1502-7.
74. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell
cycle analysis of a cell proliferation- associated human
nuclear antigen defined by the monoclonal antibody Ki-67.  J
Immunol 1984, 133(4):1710-5.
75. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C,
Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and
molecular biologic characterization of the cell proliferation-
associated nuclear antigen that is defined by monoclonal
antibody Ki-67.  Am J Pathol 1991, 138(4):867-73.
76. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP: Evaluation of cell pro-
liferation in breast carcinoma. Comparison of Ki-67 immu-
nohistochemical study, DNA flow cytometric analysis, and
mitotic count.  Cancer 1990, 65(5):1180-4.
77. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von
Smitten K: Prognostic value of Ki-67 immunolabelling in pri-
mary operable breast cancer.  Br J Cancer 1993, 8(3):579-83.
78. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syr-
janen K: The important prognostic value of Ki-67 expression
as determined by image analysis in breast cancer.  J Cancer Res
Clin Oncol 1996, 122(11):687-92.
79. Jalava PJ, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan
YU:  Ki-67 immunohistochemistry: A valuable marker in
prognostication but also a risk of misclassification. Prolifera-
tion subgroups based on Ki-67 fraction and standardized
mitotic index.  Histopathology 2006, 48:674-682.
80. Santamaria L, Martin R, Gomez V, Ingelmo I, Lopez C, Revestido R:
Stereologic estimation of Ki-67, caspase3, and GSTP1 posi-
tive cells in prostate lesions.  Image Analysis Stereol 2005,
24:77-84.
81. Linden MD, Torres FX, Kubus J, Zarbo RJ: Clinical application of
morphologic and immunocytochemical assessments of cell
proliferation.  Am J Clin Pathol 1992, 97(5 Suppl 1):S4-13.
82. Kesari AL, Chellam VG, Nair PP, Madhavan J, Nair P, Nair MK, Pillai
MR: Tumor proliferative fraction in infiltrating duct carci-
noma.  Gen Diagn Pathol 1997, 143(4):219-24.
83. Jeziorski A, Blonski JZ, Niewiadomska H: The expression of prod-
ucts of oncogens c-erbB2 and EGFR and proliferating anti-
gens Ki67 and PCNA in primary invasive ductal cancer of
female breast.  J Exp Clin Cancer Res 2000, 19(1):61-7.
84. Aaltomaa S, Lipponen P, Syrjanen K: Proliferating cell nuclear
antigen (PCNA) immunolabeling as a prognostic factor in
axillary lymph node negative breast cancer.  Anticancer Res
1993, 13(2):533-8.
85. Mourad WA, Erkman-Balis B, Livingston S, Shoukri M, Cox CE, Nico-
sia SV, Rowlands DT Jr: Argyrophilic nucleolar organizerDiagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 10 of 12
(page number not for citation purposes)
regions in breast carcinoma. Correlation with DNA flow
cytometry, histopathology, and lymph node status.  Cancer
1992, 69(7):1739-44.
86. Dasgupta A, Ghosh RN, Sarkar R, Laha RN, Ghosh TK, Mukherjee C:
Argyrophilic nucleolar organiser regions (AgNORs) in
breast lesions.  J Indian Med Assoc 1997, 95(9):492-4.
87. Aubele M, Auer G, Jutting U, Falkmer U, Gais P: Prognostic value
of quantitatively measured AgNORs in ductal mammary
carcinoma.  Anal Quant Cytol Histol 1994:211-8.
88. Rzymowska J: AgNOR counts and their combination with flow
cytometric analyses and clinical parameters as a prognostic
indicator in breast carcinoma.  Tumori 1997, 83(6):938-42.
89. Biesterfeld S, Farokhzad F, Kluppel D, Schneider S, Hufnagl P:
Improvement of breast cancer prognostication using cell
kinetic-based silver-stainable nucleolar organizer region
quantification of the MIB-1 positive tumor cell compart-
ment.  Virchows Arch 2001, 438(5):478-84.
90. Derenzini M, Ceccarelli C, Santini D, Taffurelli M, Trere D: The
prognostic value of the AgNOR parameter in human breast
cancer depends on the pRb and p53 status.  J Clin Pathol 2004,
57(7):755-61.
91. Toikkanen S, Joensuu H: AgNOR counts have no prognostic
value in breast cancer.  J Pathol 1993, 169(2):251-4.
92. Simha M, Menon M, Doctor V: Prognostic value of argyrophylic
nucleolar organiser regions (AgNORs) in breast lesions.
Indian J Cancer 1996, 33(2):76-85.
93. Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D:
Flow cytometric DNA index and S-phase fraction in breast
cancer in relation to other prognostic variables and to clini-
cal outcome.  Acta Oncol 1992, 31(2):157-65.
94. Michels JJ, Duigou F, Marnay J: Flow cytometry in primary breast
carcinomas. Prognostic impact of proliferative activity.
Breast Cancer Res Treat 2000, 62(2):117-26.
95. Fietkau R, Iro H, Tulusan AH, Dressel V, Altendorf-Hofmann A, Sauer
R:  Prognostic value of S-phase fraction in head and neck
squamous cell carcinomas and nodal negative breast carci-
nomas.  Strahlenther Onkol 1994, 170(1):13-24.
96. Zhang S, Yuan Y, Wang X: [Prognosis prediction of S-phase frac-
tion and p53, c-erbB-2, estrogen receptor, progesterone
receptor in axillary node-negative breast cancer].  Zhonghua
Wai Ke Za Zhi 1997, 35(8):475-7.
97. Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S,
Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R,
Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox
S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz
C: Low proliferative rate of invasive node-negative breast
cancer predicts for a favorable outcome: a prospective eval-
uation of 669 patients.  Clin Breast Cancer 2001, 1(4):310-4.
98. Collan Y, Klemi P, Kallioniemi OP, Joensuu H, Nordling S, Eskelinen
M: Significance of variation in DNA flow cytometric analyses
from paraffin-embedded breast cancers. Evaluation of the
grading efficiency of ploidy determination, DNA index, and
S-phase fraction.  Pathol Res Pract 1992, 188(4–5):581-6.
99. Greco S, Marsigliante S, Leo G, Storelli C: Co-expression of thymi-
dine kinase and cathepsin D in 200 primary breast carcino-
mas.  Cancer Lett 2000, 160(1):13-9.
100. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi
OP: Cathepsin D expression detected by immunohistochem-
istry has independent prognostic value in axillary node-neg-
ative breast cancer.  J Clin Oncol 1993, 11(1):36-43.
101. Billgren AM, Rutqvist LE, Johansson H, Hagerstrom T, Skoog L: The
role of cathepsin D and PAI-1 in primary invasive breast can-
cer as prognosticators and predictors of treatment benefit
with adjuvant tamoxifen.  Eur J Cancer 2000, 36(11):1374-80.
102. Rochefort H: Estrogens, cathepsin D and metastasis in cancers
of the breast and ovary: invasion or proliferation?  C R Seances
Soc Biol Fil 1998, 192(2):241-51.
103. Aaltonen M, Lipponen P, Kosma VM, Aaltomaa S, Syrjanen K: Prog-
nostic value of cathepsin-D expression in female breast can-
cer.  Anticancer Res 1995, 15(3):1033-7.
104. Ramirez-Ortega MC, Frias-Mendivil M, Delgado-Chavez R, Meneses-
Garcia A, Carrillo-Hernandez JF, Ramirez-Ugalde MT, Zeichner-
Gancz I: Expression of cathepsin D in breast cancer and its
clinical and histopathological correlations.  Rev Invest Clin 1997,
49(5):361-8.
105. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S,
Bronzert D, Huff K, Kasid A: Growth regulation of human breast
carcinoma occurs through regulated growth factor secre-
tion.  J Cell Biochem 1987, 35(1):1-16.
106. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Co-expression of epider-
mal growth factor receptor and transforming growth factor-
alpha predicts worse prognosis in breast-cancer patients.  Int
J Cancer 2000, 89(6):484-7.
107. Kumar RR, Meenakshi A, Sivakumar N: Enzyme immunoassay of
human epidermal growth factor receptor (hEGFR).  Hum Anti-
bodies 2001, 10(3–4):143-7.
108. Aziz SA, Pervez S, Khan S, Kayani N, Rahbar MH: Epidermal
growth factor receptor (EGFR) as a prognostic marker: an
immunohistochemical study on 315 consecutive breast car-
cinoma patients.  J Pak Med Assoc 2002, 52(3):104-10.
109. Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Rob-
ertson JF, Ellis IO: Epidermal growth factor receptor status in
operable invasive breast cancer: is it of any prognostic value?
Clin Cancer Res 2004, 10(7):2578.
110. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic
value of epidermal growth factor receptor (EGFR) and its
relationship to the estrogen receptor status in 1029 patients
with breast cancer.  Breast Cancer Res Treat 2002, 71(1):67-75.
111. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, Siddle
K, Harris A: Insulin-like growth factors in human breast can-
cer.  Breast Cancer Res Treat 1998, 52(1–3):175-84.
112. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark
GM, Diamandis EP: Associations between insulin-like growth
factors and their binding proteins and other prognostic indi-
cators in breast cancer.  Br J Cancer 1996, 74(8):1242-7.
113. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L: Type I
insulin-like growth factor receptor function in breast cancer.
Breast Cancer Res Treat 1998, 47(3):255-67.
114. Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M: IGF-
I in human breast cancer: low differentiation stage is associ-
ated with decreased IGF-I content.  Eur J Endocrinol 2002,
146(6):813-21.
115. Toropainen EM, Lipponen PK, Syrjanen KJ: Expression of insulin-
like growth factor II in female breast cancer as related to
established prognostic factors and long-term prognosis.  Anti-
cancer Res 1995, 15(6B):2669-74.
116. Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietanen T,
Aine R, Taskinen PJ: Estrogen and progesterone receptors in
breast cancer: relationships to tumour histopathology and
survival of patients.  Anticancer Res 1984, 4(6):383-9.
117. Barbareschi M, Doglioni C: [The immunohistochemical detec-
tion of steroid hormone receptors in breast cancer: open
problems and new perspectives].  Pathologica 2002,
94(3):115-20.
118. DeSombre ER, Kledzik G, Marshall S, Meites J: Estrogen and prol-
actin receptor concentrations in rat mammary tumors and
response to endocrine ablation.  Cancer Res 1976, 36(2 Pt
1):354-8.
119. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo
G, Andreola S, Salvadori B, Veronesi U: Biologic and clinicopatho-
logic factors as indicators of specific relapse types in node-
negative breast cancer.  J Clin Oncol 1995, 13(3):697-704.
120. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR:
Hormone receptors and proliferation in breast carcinomas
of equivalent histologic grades in pre- and postmenopausal
women.  Int J Cancer 2002, 98(1):118-27.
121. Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H,
Kimura M, Tominaga T, Iino H, Morimoto T, Tashiro H: Relative
effect of steroid hormone receptors on the prognosis of
patients with operable breast cancer. A univariate and mul-
tivariate analysis 3089 Japanese patients with breast cancer
from the Study Group for the Japanese Breast Cancer Soci-
ety on Hormone Receptors and Prognosis in Breast Cancer.
Cancer 1992, 69(1):153-64.
122. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey
RW, Robertson JF, Nicholson RI, Ellis IO: Expression and co-
expression of the members of the epidermal growth factor
receptor (EGFR) family in invasive breast carcinoma.  Br J
Cancer 2004, 91(8):1532-42.
123. Jalava P, Kuopio T, Huovinen R, Laine J, Collan Y: Immunohisto-
chemical staining of estrogen and progesterone receptors:Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 11 of 12
(page number not for citation purposes)
aspects for evaluating positivity and defining the cutpoints.
Anticancer Res 2005, 25(3c):2535-42.
124. Bocking A, Giroud F, Reith A: Consensus report of the European
Society for Analytical Cellular Pathology task force on stand-
ardization of diagnostic DNA image cytometry.  Anal Quant
Cytol Histol 1995, 17(1):1-7.
125. Auer GU, Caspersson TO, Wallgren AS: DNA content and sur-
vival in mammary carcinoma.  Anal Quant Cytol 1980:161-5.
126. Erhardt K, Auer G: Mammary carcinoma: DNA analysis in
areas showing different histological features in the same
tumor.  Acta Pathol Microbiol Immunol Scand [A] 1986, 94(1):21-8.
127. Bocking A, Chatelain R, Biesterfeld S, Noll E, Biesterfeld D, Wohlt-
mann D, Goecke C: DNA grading of malignancy in breast can-
cer. Prognostic validity, reproducibility and comparison with
other classifications.  Anal Quant Cytol Histol 1989, 11(2):73-80.
128. Friedrich K, Scheithauer J, Dimmer V, Meyer W, Theissig F, Haroske
G, Kunze KD: DNA ploidy and chromosomal imbalances in
invasive ductal breast cancer. A comparative study of DNA
image cytometry and comparative genomic hybridization
(CGH).  Anal Cell Pathol 2000, 20(2–3):69-82.
129. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic
value of DNA ploidy in 653 Japanese women with node-neg-
ative breast cancer.  Int J Clin Oncol 2001, 6(4):177-82.
130. Wong SW, Rangan AM, Bilous AM, Boyages J, Gebski V, Benson EM:
The value of S-phase and DNA ploidy analysis as prognostic
markers for node-negative breast cancer in the Australian
setting.  Pathology 1999, 31(2):90-4.
131. Bracko M, Us-Krasovec M, Cufer T, Lamovec J, Zidar A, Goehde W:
Prognostic significance of DNA ploidy determined by high-
resolution flow cytometry in breast carcinoma.  Anal Quant
Cytol Histol 2001, 23(1):56-66.
132. Yuan J, Hennessy C, Corbett IP, Dykin R, Givan AL, Shenton BK,
Henry JA, Wright C, Lennard TW: Node negative breast cancer:
the prognostic value of DNA ploidy for long-term survival.  Br
J Surg 1991, 78(7):844-8.
133. Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin
PM, Bolla M, Spyratos F: S-phase fraction and DNA ploidy in 633
T1T2 breast cancers: a standardized flow cytometric study.
Clin Cancer Res 2001, 7(4):909-17.
134. Moureau-Zabotto L, Bouchet C, Cesari D, Uzan S, Lefranc JP, Anto-
ine M, Genestie C, Deniaud-Alexandre E, Bernaudin JF, Touboul E,
Fleury-Feith J: Combined flow cytometry determination of S-
phase fraction and DNA ploidy is an independent prognostic
factor in node-negative invasive breast carcinoma: analysis
of a series of 271 patients with stage I and II breast cancer.
Breast Cancer Res Treat 2005, 91(1):61-71.
135. Collan YU, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kum-
pusalo LM, Pajarinen P, Kettunen KO: Prognostic studies in
breast cancer. Multivariate combination of nodal status, pro-
liferation index, tumor size, and DNA ploidy.  Acta Oncol 1994,
33(8):873-8.
136. Aaltomaa S, Lipponen P, Papinaho S, Klemi P, Kosma VM, Marin M,
Alhava E, Syrjanen K: Nuclear morphometry and DNA flow
cytometry as prognostic factors in female breast cancer.  Eur
J Surg 1992, 3:135-41.
137. Zajdela A, De LaRiva LS, Ghossein NA: The relation of prognosis
to the nuclear diameter of breast cancer cells obtained by
cytologic aspiration.  Acta Cytologica 1979, 23:75-80.
138. Tosi P, Luzi P, Sforza V, Santopietro R, Bindi M, Tucci E, Barbini P,
Baak JPA: Correlation between morphometrical parameters
and disease-free survival in ductal breast cancer treated by
surgery.  Appl Pathol 1986, 4:33-42.
139. Sarker S: Mean nuclear area of fine needle aspirates of pri-
mary preoperative palpable breast carcinoma using image
cytometry.  Anal Quant Cytol Histol 2002, 24(2):85-8.
140. Kronqvist P, Kuopio T, Collan Y: Morphometric grading of inva-
sive ductal breast cancer. I. Thresholds for nuclear grade.  Br
J Cancer 1998, 78(6):800-5.
141. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson
RI, Robertson JF, Blamey RW, Ellis IO: An immunohistochemical
examination of the expression of E-cadherin, alpha- and
beta/gamma-catenins, and alpha2- and beta1-integrins in
invasive breast cancer.  J Pathol 1999, 187(5):523-9.
142. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K: Expression
of E-cadherin (E-CD) as related to other prognostic factors
and survival in breast cancer.  J Pathol 1994, 174(2):101-9.
143. Asgeirsson KS, Jonasson JG, Tryggvadottir L, Olafsdottir K, Sigur-
geirsdottir JR, Ingvarsson S, Ogmundsdottir HM: Altered expres-
sion of E-cadherin in breast cancer. patterns, mechanisms
and clinical significance.  Eur J Cancer 2000:1098-106.
144. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ:
Reduced E-cadherin expression is associated with invasive-
ness and unfavorable prognosis in breast cancer.  Am J Clin
Pathol 1996, 105(4):394-402.
145. Asgeirsson KS, Olafsdottir K, Jonasson JG, Ogmundsdottir HM: The
effects of IL-6 on cell adhesion and e-cadherin expression in
breast cancer.  Cytokine 1998:720-8.
146. Berx G, Van Roy F: The E-cadherin/catenin complex: an impor-
tant gatekeeper in breast cancer tumorigenesis and malig-
nant progression.  Breast Cancer Res 2001, 3(5):289-93.
147. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R,
Lavaut M: E-cadherin quantitative immunocytochemical
assays in breast carcinomas.  J Pathol 1997, 181(3):294-300.
148. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G,
Krech R, Lelle RJ, Boecker W: Immunophenotypic and prognos-
tic analysis of E-cadherin and beta-catenin expression during
breast carcinogenesis and tumour progression: a compara-
tive study with CD44.  Histopathology 1999, 34(1):25-34.
149. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M,
Cano A: Correlation of E-cadherin expression with differenti-
ation grade and histological type in breast carcinoma.  Am J
Pathol 1993, 142(4):987-93.
150. Elzagheid A, Kuopio T, Ilmen M, Collan Y: Prognostication of inva-
sive ductal breast cancer by quantification of E-cadherin
immunostaining: the methodology and clinical relevance.
Histopathology 2002, 41(2):127-33.
151. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin
expression in invasive non-lobular carcinoma of the breast
and its prognostic significance.  Histopathology 2005,
46(6):685-93.
152. Hirohashi S: Inactivation of the E-cadherin-mediated cell
adhesion system in human cancers.  Am J Pathol 1998,
153(2):333-9.
153. Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W,
Schlag PM: Immunohistological analysis of E-cadherin, alpha-,
beta- and gamma-catenin expression in colorectal cancer:
implications for cell adhesion and signaling.  Eur J Cancer 1999,
35(1):60-5.
154. Yoshida R, Kimura N, Harada Y, Ohuchi N: The loss of E-cadherin,
alpha- and beta-catenin expression is associated with metas-
tasis and poor prognosis in invasive breast cancer.  Int J Oncol
2001, 18(3):513-20.
155. Lim SC, Lee MS: Significance of E-cadherin/beta-catenin com-
plex and cyclin D1 in breast cancer.  Oncol Rep 2002:915-28.
156. Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP,
Ponta H, Van Putten WL, Herrlich P, Henzen-Logmans SC: Prognos-
tic value of CD44 variant expression in primary breast can-
cer.  Int J Cancer 1999, 84(3):209-15.
157. Morris SF, O'Hanlon DM, McLaughlin R, McHale T, Connolly GE,
Given HF: The prognostic significance of CD44s and CD44v6
expression in stage two breast carcinoma: an immunohisto-
chemical study.  Eur J Surg Oncol 2001, 27(6):527-31.
158. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44
expression and its association with survival in breast cancer.
Am J Pathol 1993, 143(3):867-74.
159. Tempfer C, Losch A, Heinzl H, Hausler G, Hanzal E, Kolbl H, Breite-
necker G, Kainz C: Prognostic value of immunohistochemically
detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in
human breast cancer.  Eur J Cancer 1996, 32A(11):2023-5.
160. Moch H, Torhorst J, Durmuller U, Feichter GE, Sauter G, Gudat F:
Comparative analysis of the expression of tenascin and
established prognostic factors in human breast cancer.  Pathol
Res Pract 1993, 189(5):510-4.
161. Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, Morii S:
Tenascin staining positivity and the survival of patients with
invasive breast carcinoma.  J Surg Res 1993, 55(3):295-7.
162. Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M, Sakakura T:
Tenascin in breast cancer development – is epithelial
tenascin a marker for poor prognosis?  Cancer Lett 1995,
90(1):65-73.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Diagnostic Pathology 2006, 1:41 http://www.diagnosticpathology.org/content/1/1/41
Page 12 of 12
(page number not for citation purposes)
163. Hidalgo M, Eckhardt SG: Development of matrix metalloprotei-
nase inhibitors in cancer therapy.  J Natl Cancer Inst 2001,
93(3):178-93.
164. Vihinen PP, Pyrhonen SO, Kahari VM: New prognostic factors and
developing therapy of cutaneous melanoma.  Ann Med 2003,
35(2):66-78.
165. Vihinen P, Kahari VM: Matrix metalloproteinases in cancer:
prognostic markers and therapeutic targets.  Int J Cancer 2002,
99(2):157-66.
166. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G,
Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immuno-
reactive protein: a marker of aggressiveness in breast carci-
noma.  Cancer 1998, 83(6):1153-62.
167. Voltersvik P, Bostad L, Dyrhol-Riise AM, Eide GE, Rosok BI, Olofsson
J, Asjo B: Cystatin A and HIV-1 p24 antigen expression in ton-
sillar lymphoid follicles during HIV-1 infection and during
highly active antiretroviral therapy.  J Acquir Immune Defic Syndr
2006, 41(3):277-84.
168. Lah TT, Kos J, Blejec A, Frkovic-Georgio S, Golouh R, Vrhovec II,
Turk VV: The Expression of Lysosomal Proteinases and Their
Inhibitors in Breast Cancer: Possible Relationship to Progno-
sis of the Disease.  Pathol Oncol Res 1997, 3(2):89-99.
169. Greenough RB: Varying degrees of malignancy in cancer of the
breast.  J Cancer Res 1925, 9:452-463.
170. Patey DH, Scarff RW: The position of histology in the prognosis
of carcinoma of the breast.  Lancet 1928, 1:801-804.
171. Bloom HJG, Richardson WW: Histological grading and progno-
sis in breast cancer. A study of 1409 cases of which 359 have
been followed for 15 years.  Br J Cancer 1957, 11:359-377.
172. Elston CW, Ellis IO: Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up.  His-
topathology 1991, 19(5):403-10.
173. Page DL, Jensen RA, Simpson JF: Premalignant and malignant
disease of the breast: the roles of the pathologist.  Mod Pathol
1998, 11(2):120-8. Review
174. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in
early-stage breast cancer.  Oncologist 2004, 9(6):606-16. Review
175. Kronqvist P, Kuopio T, Collan Y: Morphometric grading of
breast cancer: thresholds for tubular differentiation.  Br J Can-
cer 2000, 82(10):1656-61.
176. Stenkvist B, Bengtsson E, Dahlqvist B, Eklund G, Eriksson O, Jarkrans
T, Nordin B: Predicting breast cancer recurrence.  Cancer 1982,
50(12):2884-93.
177. Eskelinen M, Collan Y, Pajarinen P, Pesonen E, Kettunen K, Nordling
S: An improved prognostic index of axillary node involve-
ment in breast cancer incorporating DNA ploidy and
tumour size.  Acta Chir Scand 1990, 156(8):521-7.
178. Collan YU, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kum-
pusalo LM, Pajarinen P, Kettunen KO: Prognostic studies in
breast cancer. Multivariate combination of nodal status, pro-
liferation index, tumor size, and DNA ploidy.  Acta Oncol 1994,
33(8):873-8.
179. Collan Y, Kuopio T, Auranen A, Linna M: Prognostication of
breast cancer by multivariate methods.  Adv Clin Path 1997,
1(4):269-273.
180. Moureau-Zabotto L, Bouchet C, Cesari D, Uzan S, Lefranc JP, Anto-
ine M, Genestie C, Deniaud-Alexandre E, Bernaudin JF, Touboul E,
Fleury-Feith J: Combined flow cytometry determination of S-
phase fraction and DNA ploidy is an independent prognostic
factor in node-negative invasive breast carcinoma: analysis
of a series of 271 patients with stage I and II breast cancer.
Breast Cancer Res Treat 2005, 91(1):61-71.